DreaMed Advisor Pro

by DreaMed Diabetes  · Based in Israel → — AI-powered clinical decision support for personalized diabetes management.
Endocrinology Family Medicine Internal Medicine
Website
Claim this tool
Is this the maker? Claim the company →

Not publicly disclosed
Regulatory Status Disclosed

Overview

DreaMed Advisor Pro is an artificial intelligence (AI)-based clinical decision support software developed by DreaMed Diabetes. It is designed to assist healthcare professionals in optimizing insulin therapy for patients with diabetes. The system analyzes comprehensive data from continuous glucose monitoring (CGM), self-monitoring blood glucose (SMBG), and insulin pumps to generate personalized recommendations for adjusting insulin pump settings, including basal rates, carbohydrate ratios, and correction factors. It also provides personalized diabetes management tips.

DreaMed Advisor Pro is indicated for use by healthcare professionals in the management of patients with Type 1 diabetes (ages 6-65) and Type 2 diabetes (ages 10 and up) who use insulin pumps or multiple daily injections (MDI) and rapid-acting U-100 insulin analogs. The recommendations generated by the software are intended to be reviewed, edited if needed, and approved by a healthcare professional before being shared with the patient, emphasizing that the tool is an adjunct to, and does not replace, clinical judgment.

The platform, often referred to as part of DreaMed’s broader endo.digital solution, aims to simplify workflows, improve operational efficiency, and provide expert-level care across various settings, including endocrinology clinics, diabetes centers, and primary care.

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Key Features

  • AI-based insulin delivery recommendations
  • Analyzes CGM, SMBG, and insulin pump data
  • Optimizes insulin pump settings (basal rate, carb ratio, correction factor)
  • Provides personalized diabetes management tips
  • Cloud-based platform
  • Recommendations reviewed and approved by healthcare professional
  • Supports Type 1 and Type 2 diabetes
  • Supports insulin pump therapy and multiple daily injections (MDI)
  • EMR integration
  • Patient app and bolus calculator

Use Cases

  • Optimizing insulin pump settings for Type 1 and Type 2 diabetes patients
  • Assisting healthcare providers in diabetes management
  • Remote patient monitoring and care
  • Empowering primary care clinicians to provide expert-level diabetes care
  • Reducing clinician burden in data interpretation and documentation
  • Improving clinical outcomes (e.g., A1c and Time in Range)

What Physicians Need to Know

Evidence Base
DreaMed Advisor Pro is an AI-based clinical decision support system for Type 1 and Type 2 diabetes, specifically for patients using insulin pumps (and recently expanded to multiple daily injections). It analyzes data from continuous glucose monitoring (CGM), self-monitoring blood glucose (SMBG), insulin pumps, and meal data. The system provides recommendations for optimizing insulin pump settings (basal rate, carbohydrate ratio, correction factor) and offers personalized diabetes management tips. It employs event-driven adaptive learning to refine its understanding for each individual patient. The device is FDA-cleared and CE-marked.
Clinical Validation Studies
Multiple studies support DreaMed Advisor Pro's safety and clinical validity. An FDA evaluation mentioned two studies (n=15 and n=6) comparing Advisor Pro to expert endocrinologists, finding generally similar recommendations. A Nature Medicine study demonstrated Advisor Pro was non-inferior to physician recommendations regarding time spent within the target glucose range (70-180 mg/dL). In this study, physicians accepted 98% of Advisor Pro's recommendations, and no serious adverse events were reported in the Advisor Pro patient group, compared to three in the physician-treated group. Further studies showed comparable magnitude of insulin dose adjustments for basal rate and carbohydrate ratio between Advisor Pro and physicians, with similar directional agreement. Real-world studies have also indicated similar average glucose levels, Time in Range, and A1C when using Advisor Pro compared to healthcare provider advice.
Override Rate Data
In a clinical study, physicians accepted 98% of the recommendations generated by DreaMed Advisor Pro, implying an override rate of approximately 2% in that context.
Guideline Update Frequency
The AI algorithm utilizes event-driven adaptive learning to continuously refine its understanding and personalize recommendations for each individual. While not a traditional 'guideline update frequency,' this adaptive learning mechanism ensures the recommendations evolve with individual patient data.
Clinical Workflow Integration
DreaMed Advisor Pro integrates with third-party Diabetes Management Systems (DMS) such as Glooko and Tidepool. Patient data from insulin pumps, CGM, and blood glucose meters are imported into the DMS, then analyzed by Advisor Pro. Recommendations are sent to the healthcare professional via the DMS for review, editing, and approval before being shared with the patient. The tool can be used for optimizing insulin pump settings during clinical visits, between visits, or as part of virtual (telemedicine) consultations. Training on the system is provided through the healthcare professional.
Decision Audit Trail
The system supports a decision audit trail as healthcare professionals review, edit, approve, or reject the recommendations generated by DreaMed Advisor Pro. This process ensures that actions taken on recommendations are recorded, providing a clear history of the decision-making process.
Physician Tip

DreaMed Advisor Pro serves as a valuable AI-powered assistant for optimizing insulin pump settings and providing personalized diabetes management tips for patients with Type 1 and Type 2 diabetes. While the system offers expert-level recommendations, it is crucial to remember that it is an adjunctive tool and does not replace clinical judgment. Always review and contextualize recommendations with the patient's full clinical status, lifestyle, and other medications. Ensure patients receive proper training on their devices and understand how their data contributes to the recommendations. Be mindful of contraindications, such as certain medications affecting CGM accuracy, or use in specific age groups/conditions.

DreaMed Advisor Pro is designed for seamless integration with various third-party Diabetes Management Systems (DMS) like Glooko and Tidepool. This integration facilitates the automatic collection and analysis of data from continuous glucose monitors, insulin pumps, and blood glucose meters. Healthcare providers should leverage these existing DMS platforms to streamline data flow and recommendation delivery, ensuring efficient workflow and patient engagement. Future integrations with Electronic Medical Records (EMR) are being explored to further optimize clinical workflows.

Details

Category Clinical Decision Support & Reference, Endocrinology & Metabolic AI
Pricing Not publicly disclosed
DeploymentCloud-based SaaS
Compliance
BAA AvailableUnknown AI-estimated
HIPAA Compliant Yes AI-estimated
FDA Status Yes AI-estimated

DreaMed Advisor Pro received De Novo FDA clearance on June 18, 2018, as an AI-based diabetes treatment decision support software for Type 1 diabetes. It later received additional clearances, including K191370 on July 18, 2019, and expanded its target population to include Type 2 diabetes and patients on multiple daily injections.
Integrations
EHR Not specified
Specialties Endocrinology, Family Medicine, Internal Medicine

What the Web Says

DreaMed Advisor Pro is an AI-powered clinical decision support system designed to assist healthcare professionals in managing Type 1 and Type 2 diabetes patients who use insulin pumps or multiple daily injections and monitor their glucose. It analyzes patient data from continuous glucose monitors (CGM), self-monitoring blood glucose (SMBG), and insulin pumps to provide personalized recommendations for optimizing insulin pump settings (basal rate, carbohydrate ratio, and correction factor) and suggesting management tips. Studies have shown that the Advisor Pro's recommendations are comparable to those of expert physicians, can improve patient outcomes, and save clinicians time.

Overall: Positive

Strengths

  • Provides AI-based, personalized insulin dosing recommendations.
  • Recommendations are comparable to those of expert physicians.
  • Can improve patient outcomes, including time in target glucose range and HbA1c levels.
  • Saves clinicians time by automating data analysis and recommendation generation.
  • Intuitive and user-friendly for endocrinologists.
  • Empowers primary care clinicians to provide expert-level endocrinological care.

Limitations

  • Requires sign-off from a healthcare provider for dosing recommendations.
  • Not intended to replace clinical judgment.
  • Users may experience confusion due to slow review publishing and overwhelming choices on review platforms like Capterra.
  • Some users on G2 find the platform complex, making it difficult for less technical marketers to adopt.
  • Potential for bias in reviews on platforms like Capterra.
  • Requires aligned clocks across CGM, insulin pump, and blood glucose meter for accurate recommendations.

Based on reviews from: dreamed.ai, accessdata.fda.gov, PMC, Business Wire, Glooko, PR Newswire, Endocrine News, DreaMed Diabetes, G2, Capterra

Last updated: 2026-07-17

Ratings & Reviews

No reviews yet. Be the first to review this tool!

Rate DreaMed Advisor Pro

Clinical Value
Ease of Use
Integration
Support & Docs
Value for Money

Press & Coverage

PR Newswire
DreaMed Diabetes Granted FDA Authorization to Market Advisor Pro, Offering Personalized Optimization of Insulin Pump Therapy
DreaMed Diabetes announced FDA authorization for DreaMed Advisor Pro, an AI-based decision support software for managing type 1 diabetes patients using insulin pumps and continuous glucose monitoring. This marks the second regulatory approval for Advisor Pro in 2018, following its EU CE Mark in February.
2018-06
The Jerusalem Post
DreaMed wins FDA clearance for AI insulin recommendation technology
DreaMed Diabetes received FDA clearance for its AI-powered insulin recommendations technology, DreaMed Advisor Pro, which assists individuals with Type 1 diabetes using insulin-pump therapy. The cloud-based software analyzes data from glucose sensors, blood glucose meters, and insulin pump data to generate personalized insulin delivery recommendations.
2019-09
Business Wire
Nature Medicine Publishes Results Reporting Equal Clinical Outcome When Using The DreaMed Advisoru00ae Compared With Physicians From Specialized Academic Diabetes Centers
A study published in Nature Medicine, conducted by the NextDREAM Consortium, found that the DreaMed Advisoru00ae AI-based decision-support system achieved glucose control statistically similar to physician-guided recommendations for type 1 diabetes patients. The study highlighted the potential of AI in remote diabetes management and the high satisfaction expressed by physicians using the Advisor.
2020-09
dreamed.ai
What's In The Nature Medicine Study Featuring Advisor Pro?
A summary of the ADVICE4U study published in Nature Medicine in September 2020, which demonstrated that DreaMed Advisor Pro's insulin dosing adjustments were non-inferior to those provided by expert physicians for children and teens with type 1 diabetes. The study also indicated high physician satisfaction and time-saving benefits.
2020-11
Business Wire
DreaMed Receives FDA Clearance for its Type 2 Diabetes AI-based Clinical Decision Support System
DreaMed announced its fourth FDA clearance for Advisor Pro, expanding its use to include patients with both type 1 and type 2 diabetes who use insulin pumps or injections. This system aims to address the shortage of endocrinologists by enabling primary care clinicians to provide expert-level care.
2021-10
diaTribe
Tired of Doing the Math Required to Constantly Adjust Your Insulin Doses? Try This Platform
DreaMed's Advisor Pro platform, an AI-powered system for insulin dosing recommendations, is now FDA approved for people with type 1 and type 2 diabetes on multiple daily injections therapy. This platform simplifies insulin adjustments and provides access to quality care, especially for those without access to endocrinologists.
2021-10
Endocrine News
FDA Clears AI-Based Type 2 Diabetes Clinical Decision Support System
DreaMed Diabetes AI LTD. received its fourth FDA clearance for its Advisor Pro AI Clinical Decision Support System, allowing its use for both type 1 and type 2 diabetes patients using insulin pumps or injections. This system aims to empower primary care clinicians to provide expert endocrinological care.
2022-01
The Times of Israel
Israeli startup offers hope in global diabetes crisis
DreaMed's AdvisorPro platform, which received FDA clearance in 2021 for both Type 1 and Type 2 diabetes, uses AI to analyze patient data from insulin pumps, blood glucose monitors, and glucose samples to provide personalized insulin recommendations. The article highlights its role in virtual communication and precision medicine.
2022-01

Videos

Product demos, reviews, and walkthroughs for DreaMed Advisor Pro.

View all on YouTube

Frequently Asked Questions

DreaMed Advisor Pro is a cloud-based digital solution that analyzes data from continuous glucose monitors (CGM), self-monitoring blood glucose (SMBG), and insulin pumps to generate personalized insulin delivery recommendations. These recommendations for basal rate, carbohydrate ratio, and correction factor are sent to the healthcare provider for review and approval, not directly to the patient, and can be utilized during in-person or telemedicine visits.
DreaMed Advisor Pro is FDA-cleared as a Class II medical device and also holds the CE Mark. It is indicated for healthcare professionals to assist in the management of patients with Type 1 diabetes (ages 6-65) who use insulin pumps and CGM/SMBG, and is also approved for Type 1 and Type 2 diabetes patients (ages 6 and up for T1D, 10 and up for T2D) on multiple daily injections therapy.
DreaMed Advisor Pro is not intended for patients using automated insulin delivery systems, those unwilling or unable to use a CGM, or individuals under 6 or over 65 years old. It is also not recommended for pregnant women, patients using insulins other than U-100, or those taking medications that may affect CGM accuracy.
While DreaMed Advisor Pro is a specialized AI-based decision support system for insulin pump and MDI therapy, other companies offer diabetes management solutions. Some alternatives in the broader insulin management software space include Glytec, Valeritas, GluCare.Health, and One Drop, though their specific functionalities and target populations may vary.
Specific pricing details for DreaMed Advisor Pro are not publicly disclosed, but its design supports increased efficiency in diabetes management. The platform aims to reduce manual tasks through EMR integration and can potentially increase the number of patient visits eligible for CPT Code reimbursement, thereby helping practices capture more revenue.
Studies have shown DreaMed Advisor Pro's insulin dosing adjustments to be non-inferior to those provided by expert physicians, with high physician satisfaction and acceptance rates. However, the system is designed as an advisory tool, and its recommendations must always be reviewed and approved by a healthcare professional, as it does not replace clinical judgment.

Compare DreaMed Advisor Pro

VS
ChatGPT vs DreaMed Advisor Pro
Clinical Decision Support & Reference Adjacent · 60/100
ChatGPT for Healthcare offers a broad, general-purpose AI assistant for various clinical and administrative tasks, including synthesizing medical evidence, drafting communications, and summarizing patient information. DreaMed Advisor Pro,…
VS
DreaMed Advisor Pro vs PeraMobile and PeraWatch
Clinical Decision Support & Reference Adjacent · 65/100
Both DreaMed Advisor Pro and PeraMobile/PeraWatch are FDA-cleared AI-powered clinical decision support tools. However, DreaMed Advisor Pro is highly specialized for optimizing insulin management in diabetes patients, while…
VS
DreaMed Advisor Pro vs EndoTool SubQ
Clinical Decision Support & Reference Adjacent · 70/100
DreaMed Advisor Pro focuses on optimizing insulin pump settings and providing personalized management tips for Type 1 and Type 2 diabetes, leveraging continuous glucose data for chronic outpatient…
VS
DreaMed Advisor Pro vs WAVE Clinical Platform
Clinical Decision Support & Reference Adjacent · 60/100
DreaMed Advisor Pro is specifically designed for personalized diabetes management, leveraging AI to optimize insulin pump settings and provide tailored tips for patients with Type 1 and Type…

Related Tools

DeepMind (Google)
Google DeepMind
Clinical Decision Support & Reference
AlphaFold is an AI system developed by DeepMind (Google) that accurately predicts protein structures and their interactions, significantly accelerating biological and medical research.
Free for non-commercial use
Tempus AI
Tempus AI
Clinical Decision Support & Reference
Tempus ECG-AI Platform uses artificial intelligence to analyze electrocardiogram data, offering advanced insights for cardiovascular diagnosis and management.
Cortex
Cortex
Clinical Decision Support & Reference
Cortex Workspace is a secure, HIPAA-compliant AI platform designed to streamline healthcare workflows and enhance decision-making for physicians.
Starts free, then $29/month for individual plan (save 10% annually). other plans: enthusiast ($99/month), business ($349/month), enterprise (contact sales).
SureMediks ProView
SureMediks (Rasimo Systems, LLC)
Clinical Decision Support & Reference
SureMediks is an AI-powered clinical decision support and metabolic health platform that automates care workflows for specialists, providing AI-generated patient summaries, automated chart review, and real-time biometric alerts.
SOAP Health
SOAP Health
Clinical Decision Support & Reference
SOAP Health is a Florida-based startup transforming patient intake with AI-powered diagnosis, offering a comprehensive solution that improves diagnosis accuracy and empowers patients and physicians.
Oxipit ChestLink
Oxipit (part of Sectra group)
Clinical Decision Support & Reference
Oxipit ChestLink is the world's first CE Class IIb-certified autonomous AI application for healthy chest X-ray reporting, capable of identifying normal studies with 99.9% sensitivity. It automates the reporting of normal chest X-rays, reducing radiologist workload and improving efficiency.

See all Clinical Decision Support & Reference tools →

Suggest an Edit → | Last Verified: 2026-04-18 | First Added: 2026-04-18
AI Tool Finder
AI-powered search. Results may not be comprehensive.